Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Habek

Showing results (201-210 of 251) with videos related to

Pageof 26
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 4, 2021
Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational studyGregor Brecl Jakob, Barbara Barun, Sarah Gomezelj, et al.
Journal of the Neurological Sciences|November 9, 2011
Systemic thrombolytic therapy in acute ischemic stroke--new experiences in spreading network of stroke units in CroatiaVesna Matijević, Zdravka Poljaković, Branko Malojčić, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|September 14, 2018
Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigueMagdalena Krbot Skorić, Luka Crnošija, Ivan Adamec, et al.
Journal of Neuroimmunology|November 21, 2017
Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapsesSimona Rolla, Stefania Federica De Mercanti, Valentina Bardina, et al.
Multiple Sclerosis and Related Disorders|September 21, 2025
The impact of national policies on reimbursement of disease-modifying therapies for multiple sclerosis on disease outcomes: Slovenia versus CroatiaGregor Brecl Jakob, Magdalena Krbot Skorić, Ivan Adamec, et al.
Multiple Sclerosis and Related Disorders|November 23, 2019
Intravenous immunoglobulins for the prevention of postpartum relapses in multiple sclerosisAlenka Horvat Ledinek, Gregor Brecl Jakob, Jana Jerše, et al.
Croatian Medical Journal|November 3, 2017
Validation and cross-cultural adaptation of the COMPASS-31 in Croatian and Serbian patients with multiple sclerosisJelena Drulović, Anđela Gavrilović, Luka Crnošija, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 29, 2016
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 monthsStefania De Mercanti, Simona Rolla, Angele Cucci, et al.
Frontiers in Immunology|March 17, 2022
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-UpSimona Rolla, Stefania Federica De Mercanti, Valentina Bardina, et al.
Multiple Sclerosis and Related Disorders|March 26, 2026
Long-term outcomes of cladribine tablets in multiple sclerosis: Treatment completion, persistence, and subsequent therapy transitions in Southeast EuropeMagdalena Krbot Skorić, Gregor Brecl Jakob, Cecilia Rajda, et al.
Pageof 26

Showing results (201-210 of 251) with videos related to

Sort By:
Pageof 26
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 4, 2021
Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational studyGregor Brecl Jakob, Barbara Barun, Sarah Gomezelj, et al.
Journal of the Neurological Sciences|November 9, 2011
Systemic thrombolytic therapy in acute ischemic stroke--new experiences in spreading network of stroke units in CroatiaVesna Matijević, Zdravka Poljaković, Branko Malojčić, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|September 14, 2018
Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigueMagdalena Krbot Skorić, Luka Crnošija, Ivan Adamec, et al.
Journal of Neuroimmunology|November 21, 2017
Lack of CD4+ T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapsesSimona Rolla, Stefania Federica De Mercanti, Valentina Bardina, et al.
Multiple Sclerosis and Related Disorders|September 21, 2025
The impact of national policies on reimbursement of disease-modifying therapies for multiple sclerosis on disease outcomes: Slovenia versus CroatiaGregor Brecl Jakob, Magdalena Krbot Skorić, Ivan Adamec, et al.
Multiple Sclerosis and Related Disorders|November 23, 2019
Intravenous immunoglobulins for the prevention of postpartum relapses in multiple sclerosisAlenka Horvat Ledinek, Gregor Brecl Jakob, Jana Jerše, et al.
Croatian Medical Journal|November 3, 2017
Validation and cross-cultural adaptation of the COMPASS-31 in Croatian and Serbian patients with multiple sclerosisJelena Drulović, Anđela Gavrilović, Luka Crnošija, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 29, 2016
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 monthsStefania De Mercanti, Simona Rolla, Angele Cucci, et al.
Frontiers in Immunology|March 17, 2022
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-UpSimona Rolla, Stefania Federica De Mercanti, Valentina Bardina, et al.
Multiple Sclerosis and Related Disorders|March 26, 2026
Long-term outcomes of cladribine tablets in multiple sclerosis: Treatment completion, persistence, and subsequent therapy transitions in Southeast EuropeMagdalena Krbot Skorić, Gregor Brecl Jakob, Cecilia Rajda, et al.
Pageof 26